- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04793399
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Multicenter, Open-label, Phase Ib/II Trial to Evaluate Safety and Efficacy for the Combination of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Myeloid Leukemia Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Begoña Maestro, PhD
- Phone Number: 209 0034911 923 700
- Email: begona.maestro@ifth.es
Study Locations
-
-
-
Madrid, Spain, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patient ≥ 18 years of age.
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legal representative) has been informed of all pertinent aspects of the study.
- Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- Newly Patient with Philadelphia chromosome positive chronic phase CML and BCR-ABL1 transcript detected at diagnosis.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
Adequate hepatic, renal and pancreatic function defined as:
- Total bilirubin within normal range or Direct bilirubin ≤ 1.5 x ULN,
- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN) or ≤5 x ULN if attributable to liver involvement of leukemia,
- Women of childbearing potential must have a negative pregnancy test documented prior enrollment. Women of childbearing potential and men must be using an adequate method of contraception.
Exclusion Criteria:
- Pregnant or lactating women,
- Participation in another clinical trial with any investigational drug within 30 days prior to study enrollment,
- Any prior medical treatment for CML, including tyrosine kinase inhibitors (TKIs), with the exception of hydroxyurea,
- Period of time since CML diagnosis longer than 6 months,
- Hypersensitivity to the active substances or to any of the excipients of the bosutinib and/or atezolizumab formulations,
- Major surgery or radiotherapy within 14 days of enrollment,
- Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease,
- Concomitant use of or need for medications known to prolong the QTc interval,
- Concomitant use with strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin), moderate CYP3A inhibitors (erythromycin, fluconazole, diltiazem), or strong CYP3A inducers (rifampin, carbamazepine, phenytoin),
History of clinically significant or uncontrolled cardiac disease, including:
- Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system for heart failure.
- Myocardial infarction within the previous 6 months,
- Symptomatic cardiac arrhythmia requiring treatment,
- Diagnosed or suspected congenital or acquired prolonged QT history or prolonged QTc. (QTcF should not exceed 500 msec),
- Grade III or IV fluid retention,
- Uncontrolled hypomagnesemia or uncorrected symptomatic hypokalemia, due to potential effects on the QTc interval,
- Uncontrolled or symptomatic hypercalcemia,
- Recent or ongoing clinically significant gastrointestinal (GI) disorder e.g. Crohn's Disease, Ulcerative Colitis or prior total or partial gastrectomy,
- Autoimmune or infectious active disease that require treatment,
- CML patient not in chronic phase at diagnosis,
- Patients with known atypical transcript. An atypical transcript is defined by the presence of any transcript in the absence of the major transcripts b3a2 (e14a2) and b2a2 (e13a2) or p210 protein,
- Patients with known resistant mutation(s) (T315I, E255K/V, Y253H, F359C/V). It is not necessary to perform mutation tests on the patient to be included in the study if they were not previously performed,
- Individuals with an active malignancy,
- Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive) and/or hepatitis C.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug.
- Patients with severe renal impairment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bosutinib-Atezolizumab Combination
Drugs to be administered: Bosutinib 400 milligram (mg)/day Oral Tablet [Bosulif 100mg oral tablets] for 1 year Atezolizumab 1680 mg/28 days [Tecentriq 840 MG in 14 ML Injection] for 1 year |
One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
Other Names:
12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Profile of Bosutinib 400 mg Daily in Combination With Atezolizumab in Participants With Chronic Myeloid Leukemia as First Line Treatments
Time Frame: through study completion, up to 7 months
|
All Adverse Events, despite their severity or causal relationship with the study medication, will be reported, graded according CTCAE v5.0 and analyzed.
|
through study completion, up to 7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Evaluate the Molecular Response (MR) Rates
Time Frame: 7 months
|
Ratio of patients that reach a Molecular response
|
7 months
|
Percentage of Participants Alive
Time Frame: 7 months
|
Percentage of patients that remain alive at different time-points over the total number or patients
|
7 months
|
Number of Confirmed MR4 and MR4.5
Time Frame: 7 months
|
Total number of patients that reach Molecular response 4 (MR4) and Molecular Response 4.5 (MR4.5)
|
7 months
|
The Rate of Confirmed MR4 and MR4.5
Time Frame: 7 months
|
Ratio of patients that reach MR4 and MR4.5
|
7 months
|
Number of Complete Cytogenetic Responses (CCyR)
Time Frame: 7 months
|
Number of patients that reach a Complete Cytogenetic Responses (CCyR)
|
7 months
|
The Rate of Complete Cytogenetic Response (CCyR)
Time Frame: 7 months
|
Ratio of patients that reach a Complete Cytogenetic Responses (CCyR)
|
7 months
|
Days to Response (CCyR, MMR, MR4, MR4.5)
Time Frame: 7 months
|
Number of days lasted since the beginning of the treatment upt to reach molecular response.
|
7 months
|
The Median Time to Response (CCyR, MMR, MR4, MR4.5)
Time Frame: 7 months
|
Average elapsed time measured for all included patients since the beginning of the treatment up until reach measurable cytogenetic or molecular response
|
7 months
|
Probability of Response (CCyR, MMR, MR4, MR4.5)
Time Frame: 7 months
|
The overall estimated probability of reaching complete cytogenetic response or molecular response MMR, MR4 or MR4.5
|
7 months
|
Number of Overall Surviving Patients
Time Frame: 7 months
|
Number of the overall surviving patients
|
7 months
|
Number of Progression-free Survival Patients
Time Frame: 7 months
|
The following events are considered disease progression:
|
7 months
|
Number of Failure-free Survival Patients
Time Frame: 7 months
|
Number of the failure-free survival patients
|
7 months
|
Number of Event-free Survival Patients
Time Frame: 7 months
|
Number of the event-free survival patients
|
7 months
|
Phenotypical Assays of Cell Characterization
Time Frame: 7 months
|
Phenotypical assays of the cell characterization
|
7 months
|
Phenotypical Assays of Differentiation, Maturation and Proliferation NK Cells Markers
Time Frame: 7 months
|
Phenotypical assays of the differentiation, maturation and proliferation NK cells markers
|
7 months
|
Phenotypical Assays of CD4+ T Cells Activation Markers
Time Frame: 7 months
|
Phenotypical assays of the CD4+ T cells activation markers
|
7 months
|
Phenotypical Assays of Predictive Markers of CML Relapse
Time Frame: 7 months
|
Phenotypical markers assessment for relapse included
|
7 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Valentin Garcia, Dr., Hospital Ramon y Cajal
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Tyrosine Kinase Inhibitors
- Atezolizumab
- Bosutinib
Other Study ID Numbers
- ZEROLMC-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Phase-Chronic Myeloid Leukemia
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
ChemGenex PharmaceuticalsTerminatedMyeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast PhaseUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myelogenous Leukemia - Chronic PhaseChina
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Korean Society of HematologyNot yet recruitingChronic Myeloid Leukemia, Chronic Phase
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingCML, Chronic Phase | CML, Accelerated PhaseChina
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveUnited States, Canada, Australia, Puerto Rico
Clinical Trials on Bosutinib 400 MG Monotherapy
-
Dr. Reddy's Laboratories LimitedXenoPort, Inc.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
Daiichi Sankyo, Inc.CompletedHealthy VolunteersUnited States
-
Humanis Saglık Anonim SirketiNovagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. StiCompleted
-
Medicines for Malaria VentureAbbVieCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
GlaxoSmithKlineCompletedPsoriasisGermany, United Kingdom
-
Guangdong Raynovent Biotech Co., LtdCompleted
-
CTI BioPharmaCovanceCompleted